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Abstract
The arterial duct is a short vessel that connects the junction of the main and left pul-
monary artery to the descending aorta just distal to the left subclavian artery. In foetal 
life, it is an essential vascular structure that allows oxygenated blood to bypass the pul-
monary circulation, since the lungs are not involved in oxygenation and enter systemic 
circulation. Persistent patency of the arterial duct after 3 months of age in term infants 
is a common form of congenital cardiovascular abnormality representing 5–10% of all 
congenital heart defects. Also, persistent patency of the arterial duct is a common prob-
lem in very premature sick neonates, which is associated with significant morbidity 
and mortality and is attributed to immaturity of the duct and associated co-morbidities 
in this population.
Keywords: patent arterial duct, congenital heart disease, premature neonate, ibuprofen, 
indomethacin, transcatheter closure, surgical ligation, Eisenmenger syndrome, foetal 
cardiovascular physiology, transitional circulation
1. Introduction
The arterial duct is a short vessel that derives from the distal portion of the left sixth embry-
onic arch and connects the junction of the main and left pulmonary artery to the descending 
aorta just distal to the left subclavian artery (Figures 1–3) [1–3]. This process is complete by 
the eighth week of foetal life and is necessary for normal foetal circulation and intrauterine 
survival [1]. During development, the arterial duct allows oxygenated blood to bypass the 
pulmonary circulation, since the lungs are not involved in oxygenation and enter directly 
into systemic circulation. After birth, the arterial duct closes via a complex biphasic process 
and becomes the ‘ligamentum arteriosum’ [4]. The arterial duct closes spontaneously in about 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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90% of full-term infants during the first 48 hours of life [5]. Persistent patency beyond the 
third month of life in term infants is a common form of congenital heart disease with an 
incidence of 1–2000 representing 5–10% of all congenital heart anomalies [1–3].
Figure 1. Saggital view of the foetal heart showing the pulmonary trunk, the aorta and the arterial duct at the same plane 
and the connection of the junction of the main and left pulmonary artery to the descending aorta just distal to the left 
subclavian artery. PT: pulmonary trunk; RPA: right pulmonary artery; LPA: left pulmonary artery; PDA: patent arterial 
duct; Dao: descending aorta.
Figure 2. Saggital views of the foetal heart showing the aortic and the ductal arch. The scan angle between the ductal 
arch and the thoracic aorta ranges between 10° and 19° during pregnancy. Note that the ductal arch has a similar size 
to the aortic arch in the foetus. Left: Aortic arch view. The ‘candy cane-like’ aorta gives rise to the three head and neck 
vessels, i.e. the brachiocephalic, left common carotid and left subclavian arteries [3, 4]. Right: Ductal arch view. The 
arterial duct connects the main pulmonary artery to the descending aorta, forming a ‘hockey stick-shaped’ arch. LV: left 
ventricle; RV: right ventricley; PDA: patent arterial duct; Dao: descending aorta.
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Persistent patency of the arterial duct is a common problem in sick premature and extremely 
low-birth weight neonates, having an incidence of 65% in those weighing less than 1 kg and is 
associated with increased morbidity and mortality related to the consequences of a significant 
left-to-right shunt [6, 7].
Patent arterial duct (PAD) may present in adults with dyspnoea due to cardiac failure, pul-
monary hypertension/Eisenmenger syndrome, infectious endarteritis, atrial fibrillation or be 
an incidental finding on routine physical examination or on transthoracic echocardiography 
performed for other purposes in an asymptomatic subject (‘a silent duct’) [8].
1.1. Normal histology and changes after birth
The arterial duct is a muscular artery and its histology is easily distinguishable from that 
of the aorta and pulmonary artery, the walls of which are composed of elastic fibers, which 
are arranged circumferentially [9]. The internal surface of the normal arterial duct is lined 
by a layer of endothelial cells that overlies an internal elastic lamina. The elastic lamina is 
fragmented and sometimes split up into several layers and is interrupted by intimal cushions 
that lie underneath it (Figure 4). The media of the ductal wall consists of two layers of smooth 
muscles, which have spiral arrangements in opposite directions. The outer spiral is more 
acute, giving the impression of circularly arranged smooth muscle fibres, whereas the inner 
spiral is more gradual, so the fibres appear longitudinal [9].
In utero, the patency of the arterial duct is maintained mainly due to the low oxygen tension 
in the foetal blood and the increased concentrations of cyclooxygenase-mediated products of 
arachidonic acid metabolism, primarily prostaglandin E
2
 and prostacyclin [2, 10, 11]. These 
are produced by the duct itself and the placenta and their metabolism, which is normally 
performed by the pulmonary parenchyma is low, as the lungs are non-functional [2, 10, 11].
Figure 3. The ‘3 vessel and tracheal view’ (3VT) is a standardised transverse plane of the upper mediastinum 
demonstrating simultaneously the course and the connection of both the aortic and ductal arches and a cross-section of 
the superior vena cava [1, 2]. Left: The three vessels are arranged in an oblique line, with the pulmonary artery in the 
most anterior position, the superior vena cava in the most posterior position and the aorta in between. Right: Transverse 
view of aortic and ductal arch identifies two vessels merging at the isthmus to form a V-shaped structure and Doppler 
imaging shows that blood flow in both arches has the same direction (blue colour). Tr: trachea; SVC: superior caval vein; 
Ao: aorta; PA: pulmonary artery.
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After birth, the arterial duct closes via a complex biphasic process. During the first stage, 
constriction of the smooth muscle in the media of the ductal wall takes place, producing 
shortening and thickening of the wall. These changes induce significant ischaemic hypoxia, 
which leads to production of several angiogenic factors and inflammatory mediators [9]. The 
intimal cushions disrupt the internal elastic membrane, form swollen protrusions into the 
ductal lumen, gradually unite and finally obliterate the lumen [9]. During the second stage of 
closure, proliferation of connective tissue in the intima and media takes place alongside with 
atrophy of smooth muscle cells and finally the arterial duct is transformed into a non-contrac-
tile ligament (the ‘ligamentum arteriosum’) [9].
The architecture of the arterial duct predisposes the tissue to contraction and lumen oblitera-
tion under appropriate signals and conditions, such as the increase in oxygen tension that 
normally takes place after birth [15]. Furthermore, there are various vasoactive substances 
such as bradykinin and endogenous catecholamines, which also mediate ductal closure after 
birth [9]. Prostaglandins exert an effect on ductal wall that is opposite to oxygen, causing 
relaxation of the smooth muscles, and inhibit the obliteration of the lumen [9]. However, their 
concentrations normally decrease after birth due to the removal of the placenta and their 
metabolism by the lungs [2].
1.2. Epidemiology and aetiology
In normal term infants, the closure of the arterial duct may be delayed until 3 months of life, 
after which the incidence of spontaneous closure is very low [1, 3]. If the duct remains open 
beyond 3 months of life in full-term infants, it is termed ‘persistently patent arterial duct’ and 
its patency has been attributed to inherent abnormality of the ductal tissue and/or signalling 
pathways that normally trigger its closure [12]. However, the exact mechanisms as to why the 
duct will not close in some full-term infants remain unknown [3].
Figure 4. The ‘Krichenko Classification’ for anatomical classification of the PDA.
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Also, the incidence of PAD in infants and children born at full term is not precisely known 
due to the fact that most subjects are asymptomatic. Before the widespread use of echocar-
diography, the incidence of clinically evident persistent PAD was reported to be about 1 in 
2000 births, which accounts for approximately 5–10% of all congenital heart defects [1–3]. If 
cases detected incidentally by echocardiography are included, the incidence will be much 
higher and is estimated to be 1:500 [1, 3].
The female-to-male ratio for PDA is about 2:1. In addition, PAD occurs with increased fre-
quency in several genetic syndromes, including Down syndrome (trisomy 21), trisomy 18, 
Char syndrome (autosomal dominant), Carpenter syndrome (single gene mutation), Holt-
Oram syndrome (autosomal dominant) and incontinentia pigmenti (X-linked). Although, 
most cases are sporadic, there is increasing evidence that genetic factors are involved in many 
patients. Prenatal infection, such as rubella, may also play a role in some cases [1, 3].
1.3. Anatomy and histology
A universally accepted system for anatomical classification of the PAD is the ‘Krichenko 
Classification’, which is based on the angiographic appearance of the duct [14]. The five 
Krichenko PDA subtypes are: type A (conical), type B (window type), type C (tubular), 
type D (complex) and type E (elongated), with a relative incidence of approximately 85% 
for type A, 10% for both types D and E combined and 5% for both types B and C combined 
[13] (Figure 5). Most commonly, a patent arterial duct occurs as an isolated congenital heart 
defect. Histologically, the internal elastic lamina of the PAD is generally intact and the intimal 
cushions are absent or are less well formed than normal [14] (Figure 6). Morphologically, 
a progressive transformation of the duct wall to the elastic-type artery has been observed 
with light microscopy. In this transformation, three stages were determined—stage I: laminar 
elastosis of the intima; stage II: same as stage I plus incomplete elastic transformation of the 
media and stage III: fully developed elastic-type artery [14].
However, in normal subjects, selective constriction of arterial duct suggests the presence of 
highly specialised contractile mechanisms. Indeed, smooth muscles in arterial duct are more 
differentiated compared to those in other arteries, which may be one of the cellular mecha-
nisms responsible for the closure of the arterial duct after birth [15].Postnatal constriction 
Figure 5. Histologic sections through two normal ducts from neonates. (a)This longitudinal section shows the distinctive 
appearance of the ductal wall composed mainly of smooth muscle compared to the walls of the aorta and pulmonary 
trunk, which are composed primarily of elastic tissue. (b) This transverse section shows the intimal cushions (c) that 
protrude towards the ductal lumen. m = media. [trichrome stain].
Patent Arterial Duct
http://dx.doi.org/10.5772/intechopen.79956
9
Figure 7. Left: Normal (right-to-left) ductal Doppler in a 22-week + 5–day-old foetus. Right: Left-to-right ductal Doppler 
in an extremely premature neonate showing a similar pulsatile unrestrictive, but reversed, pattern of flow.
of the full-term arterial duct arteriosus produces cell death and remodelling of its wall. The 
extensive degree of cell death that occurs in the newborn duct after birth is associated primar-
ily with ATP depletion. The increased glycolytic capacity of the immature duct may enable it 
to tolerate episodes of hypoxia and nutrient shortage, making it more resistant to developing 
postnatal cell death and permanent obliteration of its lumen [16].
1.4. Pathophysiology and clinical picture
After birth, systemic resistance increases markedly as the placenta is disconnected from the 
systemic circulation, and pulmonary vascular resistance decreases significantly over time 
[10, 11, 17]. Therefore, in patients in which the arterial duct remains persistently patent, the 
direction of flow is left-to-right and the amount of shunt is determined by the difference in 
systemic and pulmonary vascular resistance, as well as by the resistance to blood flow deter-
mined by the residual diameter, geometry and distensibility of the duct (Figures 7–9) [18]. 
Figure 6. Histology image showing part of a persistently patent duct cut in cross-section. The internal elastic lamina is 
intact and appears as a black line lining the ductal lumen. Intimal cushions are barely formed, leaving a widely patent 
lumen. [elastic van Geison stain].
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In patients with isolated persistency of the arterial duct, the clinical manifestations and com-
plications are mainly related to the degree of pulmonary over-circulation and left ventricular 
volume overload [1–3, 12]. The increased pulmonary venous return to the left heart results in 
increased left ventricular volume and end-diastolic pressure, as well as increased left atrial 
size and pressure. The left ventricle compensates by increasing stroke volume, and eventually 
may hypertrophy in order to normalise wall stress [1].
Most patients are asymptomatic when the duct is small. In a moderate-to-large duct, infants may 
have increased work of breathing, which becomes manifest as fast or laboured breathing and 
tiredness during feeds. In older children, there may be a history of exertional dyspnoea. Large 
shunts may lead to failure to thrive, recurrent respiratory tract infections and congestive heart 
failure [1, 2]. In patients with long-standing moderate-to-large left-to-right shunt, irreversible 
pulmonary vascular changes may occur over time, secondary to prolonged exposure to high 
pulmonary blood flow [3, 12]. These changes include arteriolar medial hypertrophy, intimal 
proliferation and fibrosis. When pulmonary arterial pressure exceeds systemic pressure, the 
flow across the duct is reversed and right-to-left shunting occurs (Eisenmenger syndrome) [18].
Figure 8. Left: Early postnatal ductal Doppler, which is bi-directional with predominant left-to right, suggesting a 
decline of pulmonary resistance after birth. Right: Late postnatal restrictive ductal Doppler, which is pure left-to right, 
suggesting further decline of pulmonary resistance and a normal adaptation to extra-uterine life.
Figure 9. Left: ‘ductal shot’ which is a modified shot axis view showing a patent arterial duct measuring 1.53 mm (the ‘three 
leg stool appearance’). Right: Non-restrictive ductal Doppler in the same patient. Ao: aorta; PDA: patent arterial duct; Dao: 
descending aorta. Ao: aorta; PT: pulmpnary trunk; Dao: descending aorta; PDA device: Amplatzer duct occluder.
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1.5. Physical examination
Physical examination findings depend on the size of the patent arterial duct and the presence 
of associated defects. A small PAD presents with a continuous ‘machinery’ type murmur, 
which is best heard at the left infraclavicular area [1–3, 12]. In case of a large duct with pure 
left-to-right shunt, besides the classic ‘machinery’ murmur, there may be bounding periph-
eral pulses due to hyperdynamic circulation and a wide pulse pressure. Adults with a large, 
non-restrictive PDA, however, may have suprasystemic pulmonary artery pressure and 
develop Eisenmenger physiology with a right-to-left shunt. In these patients, the continu-
ous ‘machinery’ murmur is no longer audible. They may develop differential cyanosis, with 
more profound desaturation of the lower extremities associated with clubbing, which is more 
prominent in the toes. This represents the most specific physical sign of a large PAD associ-
ated with shunt reversal [20]. On the contrary, a trivial arterial duct is totally asymptomatic, 
flow through it is minimal and non-turbulent and thus no murmur is audible [1–3].
1.6. Specific age groups
1.6.1. Patent arterial duct in the preterm neonate
Prematurity increases the likelihood of persistent ductal patency, which is seen in about 30% of 
very low-birth weight and up to 65% of extremely low-birth weight infants [21]. The incidence 
of patent arterial duct increases with decreasing gestational age. The inherent immaturity in 
the muscular wall of the duct in preterm infants is associated with decreased oxygen sensi-
tivity and increased sensitivity to prostaglandins and nitric oxide, leading to reduced ductal 
constriction. Without sufficient enough physiologic hypoxia to promote vascular remodelling, 
anatomic closure will not occur and the duct may fail to close or reopen after closure [21]. Also, 
very premature infants usually have respiratory distress syndrome and relatively low oxygen 
levels after birth, contributing to delayed effective ductal closure [10, 22]. Although the duct, 
the preterm newborn continues to respond to PGE2 after birth, it becomes less dependent on 
prostaglandins and more dependent on other vasodilators during the weeks following deliv-
ery. This could explain why the effectiveness of prostaglandin inhibitors, as a pharmacologic 
treatment to promote ductal closure, wanes with increasing postnatal age [23].
The pathophysiologic features of a PAD depend both on the magnitude of the left-to-right 
shunt and on the cardiac and pulmonary responses to the shunt. The consequences may 
include pulmonary over-circulation and/or systemic hypoperfusion [24]. Despite the ability 
of the left ventricle to increase its output in the setting of a significant left-to-right shunt, ‘duc-
tal steal’ occurs, resulting in hypoperfusion of peripheral organs (Figures 10 and 11). Also, 
the decreased ability of the preterm infant to maintain active pulmonary vasoconstriction 
combined by the use of surfactant replacement therapy in preterm infants with respiratory 
distress syndrome lead to a more rapid drop in pulmonary vascular resistance and exacerbate 
the magnitude of left-to-right shunt. This results in lung congestion and volume overload of 
the preterm left atrium and ventricle (Figure 12) [22]. Although 75% of premature infants 
with PAD at discharge from the neonatal intensive care unit will have spontaneous closure 
during the first year of life, prolonged exposure to PAD has been associated with significant 
morbidity, and a four to sevenfold increase in mortality [21]. Complications associated with a 
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patent arterial duct in preterm infants include peri/intraventricular haemorrhage, necrotising 
enterocolitis, renal failure, congestive heart failure with hypotension and metabolic acidosis, 
haemorrhagic pulmonary oedema and prolonged ventilator dependence with subsequent 
chronic lung disease [21].
Whether to treat or not, as well as when to treat a PAD, has been a controversial topic for 
the past decade [21, 24, 25]. It has become apparent from systematic review of the literature 
that there is no clear evidence of effect on long-term outcomes of treating PAD, which some 
authors consider a physiologic phenomenon in sick preterm infants [23, 24].
Figure 10. Abnormal middle cerebral artery Doppler with absence of end-diastolic flow (left) and reversal of end-
diastolic flow (right) predisposing to intra/periventricular haemorrhage.
Figure 11. Abnormal superior mesenteric artery Doppler with absence of end-diastolic flow predisposing to necrotising 
enterocolitis.
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Non-steroidal anti-inflammatory drugs have been traditionally used to close PADs to prevent 
associated complications [21, 24]. As a large proportion of the PADs in preterm infants will 
spontaneously close within the first few days, in recent years emphasis has been given to 
targeted treatment of PADs when considered haemodynamically significant based on clinical 
and echocardiographic criteria. The two most commonly used treatment options are intrave-
nous ibuprofen and intravenous indomethacin [21, 24]. Recent observational studies suggest 
that paracetamol may have a role in PAD closure in infants who are resistant to conventional 
treatment or those with contraindications to conventional medical therapy [26]. A recent 
meta-analysis which included preterm infants treated with intravenous or oral indomethacin, 
ibuprofen, acetaminophen, placebo or no treatment concluded that high doses of oral ibu-
profen are associated with a higher likelihood of closure of a haemodynamically significant 
PAD versus standard doses of intravenous ibuprofen or intravenous indomethacin. However, 
placebo or no treatment did not significantly change the risk of mortality, necrotising entero-
colitis or intraventricular haemorrhage [27].
1.6.2. Adults with untreated patent arterial duct
The mortality in adults with an unoperated PAD is estimated to be 1–1.5% in the third decade, 
2–2.5% in the fourth decade and increases by 4% per year thereafter, with 33% mortality at the 
age of 40 and 60% at 60 years of life [28]. Untreated PAD may cause congestive heart failure 
due to left heart volume overload and increased pulmonary blood flow; atrial fibrillation 
or flutter due to atrial enlargement; infective endocarditis/endarteritis, which is more com-
mon in the second or third decade of life; lower respiratory tract infections; calcification and 
pulmonary vascular disease/Eisenmenger syndrome [20]. Adult patients with Eisenmenger 
syndrome have dyspnoea on exertion, fatigue, syncope due to low systemic cardiac output, 
neurologic abnormalities due to secondary erythrocytosis and hyperviscosity, right heart fail-
ure, arrhythmias and haemoptysis due to pulmonary infarction [19].
Other more uncommon complications include aneurysmal dilatation of the duct, recurrent 
laryngeal nerve paralysis due to compression from a dilated pulmonary artery, peripheral 
emboli and exceedingly rarely aortic or pulmonary artery dissection [19, 20, 29].
Figure 12. Left atrial dilatation (left) as a result of a significant left-to-right shunt with left atrium in systole to aorta in 
diastole ratio (right), LA/Ao = 1.67 (normal values<1.40). RA: right atrium; LA: left atrium; Ao: aorta.
Congenital Heart Disease14
Echocardiography is the key diagnostic imaging modality; however, it may be difficult in 
patients with Eisenmenger physiology [30]. Echocardiography defines the presence and the 
size of the PAD, the effect of the shunt on the left atrium and left ventricle, the pulmonary 
circulation and any associated lesions [31]. Magnetic resonance imaging (MRI) or computed 
tomography (CT) is indicated to evaluate pulmonary artery anatomy or to obtain more precise 
left ventricular volumes. Cardiac catheterisation is reserved for cases with signs of pulmonary 
hypertension on echocardiography to estimate pulmonary vascular resistance and assess the 
reactivity of the pulmonary vascular bed [30, 31].
Transcatheter occlusion is the treatment of choice, even if operation for associated anomalies 
has been scheduled. In adults, the duct is often calcified and the tissue in the area of the aortic 
isthmus and pulmonary artery is friable, making surgical ligation difficult and more hazard-
ous compared to paediatric patients [30, 31]. Surgical ligation is thus reserved for patients 
with very large ducts, those with difficult anatomy or aneurysmal dilatation [30].
Arterial duct occlusion eliminates volume overload of the left ventricle and pulmonary over-
circulation, treats congestive heart failure and prevents both the development of obstructive 
pulmonary vascular disease/Eisenmenger syndrome and subacute endocarditis/endarteritis 
[1–3, 29]. Routine follow-up is recommended every 3–5 years for patients with a small PAD 
without evidence of left-heart volume overload. Also, follow-up approximately every 5 years 
for patients who received a device is recommended because of the lack of long-term data [20].
2. Management: surgical and transcatheter techniques
Over the past 15–20 years, transcatheter closure of PADs has become the standard of care for 
most patients and surgery is reserved for those with very large ducts or low-weight babies 
(Figures 13 and 14) [6]. A number of studies have been published reporting experience with 
transcatheter PAD closure, in particular using detachable coils and the Amplatzer ductal 
occluder device [6, 29]. In the reported series of transcatheter closure, major procedural events 
occurred in 1.0% of cases, a risk not related to ductal size [6]. The procedural risks specifically 
associated with closure of a silent duct are not known.
According to the scientific statement from the American Heart Association (AHA) concerning 
cardiac catheterisation and intervention in paediatric cardiac disease, transcatheter PAD closure 
is indicated for the treatment of a moderate-sized or large PAD with left-to-right shunt associ-
ated with congestive heart failure, failure to thrive, an enlarged left atrium or left ventricle or 
pulmonary over-circulation, provided the anatomy and patient size are suitable (Figure 15) [29].
Transcatheter PAD occlusion is considered reasonable in the presence of a small left-to-right 
shunt with normal-sized heart chambers when the PAD is audible by standard auscultation 
techniques [29]. Small PADs without haemodynamic overload are generally closed because of 
the risk of subacute bacterial endocarditis [29, 32].
In the current era, transcatheter techniques are used to close PADs in most patients who weigh 
more than 5–6 kg [33]. The size and stiffness of the delivery sheath limit this approach in 
infants with low body weight; however, transcatheter occlusion has been applied with good 
success in symptomatic infants as small as 1800 g to avoid thoracotomy and the complications 
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associated with surgical ligation [34]. Excellent results have been achieved using coil devices 
or plugs implanted into the arterial duct via the descending thoracic aorta using a transfemoral 
approach. Potential complications include device embolization, vascular injury, partial occlu-
sion of the left pulmonary artery or aorta by the plug, and residual shunting [33]. Surgical 
strategies are applied for the larger arterial duct. The most typical surgical management of 
a PAD in older children is with ligation and division of the duct through a left thoracotomy.
Figure 14. Patient of Figure 9 after successful amplatzer duct occlusion showing the device in correct position. Left: 
aortic arch view. Right: short axis view.
Figure 13. Angiography prior to transcatheter closure attempt showing a large patent arterial duct.
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Video-assisted thoracoscopic PAD ligation is a less invasive technique that may be consid-
ered for selected patients [35]. Unsuccessfully performed thoracoscopic surgeries can safely 
be converted to conventional thoracotomy. Video-assisted thoracoscopic surgery is a less 
invasive approach, leads to a better aesthetic effect and lower surgical complication rate [35].
The postoperative management of older infants and children is usually quite straightforward. 
Most patients have a substantial improvement in the haemodynamic efficiency of the heart 
following this operation and do not require inotropic support or significant manipulation of 
the systemic and pulmonary vasculature in the perioperative period [33].
In premature babies and small infants, simple double ligation is performed. Surgical PAD 
closure may be considered for patients who do not respond to medical management, or if 
medical management is contraindicated [33]. A subset of premature neonates develop tran-
sient haemodynamic instability characterised by left ventricular dysfunction, low cardiac 
output syndrome and the need for increased respiratory support. Patients weighing less 
than 1000 g are at particular risk, likely related to the immaturity of the myocardium [33]. 
Although uncommon, a number of complications may develop following surgical PAD liga-
tion. Residual shunting may uncommonly occur through a PAD that has been ligated but not 
divided. Because the recurrent laryngeal nerve travels around the PAD, consideration should 
be given to prevent potential injury to the nerve during duct ligation [33].
3. Current controversies
3.1. Infective endocarditis/endarteritis prophylaxis
Subacute bacterial endocarditis/endarteritis has been reported in both symptomatic and 
asymptomatic patients with a patent arterial duct; however, the necessity for subacute endo-
carditis prophylaxis remains to be defined [36–38]. Infective endocarditis is an uncommon 
but life-threatening disease and prevention is preferable to treatment of established infection. 
Figure 15. Left: Angiography during transcatheter closure attempt with an Amplatzer duct occluder. Right: angiography 
showing successful PAD closure in the same patient.
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Bacteraemia with organisms known to cause infective endocarditis occurs commonly in asso-
ciation with invasive dental, gastrointestinal or genitourinary tract procedures. However, infec-
tive endocarditis is much more likely to result from frequent exposure to random bacteraemias 
associated with daily activities. Although prophylaxis may prevent an exceedingly small num-
ber of cases of infective endocarditis in individuals who undergo a dental, gastrointestinal tract 
or genitourinary tract procedure, the risk of antibiotic-associated adverse events exceeds the 
benefit. Therefore, maintenance of optimal oral health and hygiene may reduce the incidence 
of bacteraemia from daily activities and is more important than prophylactic antibiotics for a 
dental procedure to reduce the risk of infective endocarditis. These were the primary reasons 
for the revision of the infective endocarditis prophylaxis guidelines of the American Heart 
Association Committee on Rheumatic Fever, Endocarditis and Kawasaki disease, which does 
not recommend routine subacute bacterial endocarditis prophylaxis for unrepaired PAD [32].
The impacts of the application of the 2007 AHA antibiotic prophylaxis guidelines for infective 
endocarditis were studied using a nationally representative cohort of paediatric patients in 
the US. The data did not demonstrate significant changes on the overall incidence or sever-
ity of paediatric infective endocarditis in the period 2001–2012 [37]. However, a significant 
increase in disease incidence trend due to viridans group streptococci was observed in the 
10–17 age group in the postguideline period. Infective endocarditis due to viridans group 
streptococci is presumed to result principally from bacteraemia during dental work, which is 
more common in older children. It should be noted that the absence of overall change in infec-
tive endocarditis incidence from pre- to postguideline might in part reflect poor adherence to 
the 2007 AHA policy [39, 40].
3.2. The ‘silent arterial duct’
With the advent of novel ultrasound technologies, the incidence of persistent patency of the 
arterial duct is expected to become much higher. If cases detected incidentally on transtho-
racic echocardiography performed for other purposes are included, the incidence is estimated 
to be 1:500 individuals [1–3, 20]. When the duct becomes very small, flow is diminished and 
non-turbulent and thus no murmur is audible. The very small duct, which is identified inci-
dentally in asymptomatic subjects and produces no murmur on auscultation, is termed ‘the 
silent arterial duct’ [10, 29].
There is still controversy related to the need of closure of a silent arterial duct which is associ-
ated with a small left-to-right shunt, a normal heart size and an inaudible murmur (AHA 
Class of recommendation IIb; Level of evidence C) [29]. There are few data supporting signifi-
cant benefits of occluding it solely to prevent subacute infective endocarditis. A tiny patent 
arterial duct does not have a high enough velocity of flow through it to cause endothelial 
damage, which is the substrate for bacterial growth [20]. According to the European Society 
of Cardiology (ESC), device closure should be considered in small PADs with continuous 
murmur, normal left ventricular and pulmonary artery pressure (Level of Evidence IIa; Class 
of Recommendation C C), but should be avoided in the silent duct (Level of Evidence III; 
Class of Reccommendation C) [29].
Congenital Heart Disease18
4. Conclusion
A patent arterial duct is a cardiovascular disorder documented in patients of all ages, from 
extremely premature infants to elderly subjects [41, 42]. Currently, the widespread availabil-
ity of echocardiography has resulted in improved detection and detailed characterisation of 
the size of a PAD, the effects on the left atrium and left ventricle, the pulmonary circula-
tion and any associated lesions. The haemodynamic consequences of PDA are analogous to 
the magnitude and the direction of the shunt, which depends on the flow resistance within 
the duct, and the dynamic pressure gradient between the pulmonary and systemic blood 
flow [42]. Catheter occlusion is the treatment of choice and surgical ligation is reserved for 
patients with very large ducts or when interventional closure is not feasible. However, the 
optimal management of the ‘silent arterial duct’ remains controversial and requires further 
investigation.
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A. Appendix 1
[1] The application of classification of recommendations and level of evidence according to 
AHA/ACC is published in Circulation [43].
[2] The recommendations for formulating and issuing ESC Guidelines can be found on the 
ESC Web Site. (http://www.escardio.org/ guidelines-surveys/esc-guidelines/about/Pages/rules 
writing.aspx).
B. Appendix 2
Further reading regarding assessment of a PAD with foetal and neonatal echocardiography. 
See Ref. [43].
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